Oral Anti-CD3 for the Treatment of Active Ulcerative Colitis

Trial Profile

Oral Anti-CD3 for the Treatment of Active Ulcerative Colitis

Completed
Phase of Trial: Phase I/II

Latest Information Update: 16 Jun 2017

At a glance

  • Drugs Muromonab CD3 (Primary) ; Omeprazole
  • Indications Ulcerative colitis
  • Focus Adverse reactions; Pharmacodynamics
  • Most Recent Events

    • 09 May 2013 Planned end date changed from 1 Nov 2013 to 1 Dec 2013 as reported by ClinicalTrials.gov
    • 09 May 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov
    • 30 Nov 2012 Planned End Date changed from 1 Feb 2012 to 1 Nov 2013 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top